Article Text

Download PDFPDF
5T4 oncofetal antigen expression in ovarian carcinoma
  1. E. Wrigley*,
  2. A. T. Mcgown,
  3. J. Rennison*,
  4. R. Swindell,
  5. D. Crowther*,
  6. T. Starzynska§ and
  7. P. L. Stern§
  1. * CRC Department of Medical Oncology, Christie Hospital,
  2. CRC Department of Experimental Chemotherapy, Paterson Institute,
  3. CRC Department of Medical Statistics, Christie Hospital,
  4. § CRC Department of Immunology, Paterson Institute, Manchester, UK
  1. Address for correspondence: Dr P. L. Stern, CRC Department of Immunology, Paterson Institute, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 9BX, UK.


5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P < 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease-free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.

  • 5T4 oncofetal antigen
  • ovarian carcinoma
  • survival.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.